Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 18;11(3):787.
doi: 10.3390/microorganisms11030787.

Challenges and Recent Advancements in COVID-19 Vaccines

Shao-Cheng Wang  1   2 , Chung-I Rai  3   4 , Yuan-Chuan Chen  5   6   7
Affiliations
Review

Challenges and Recent Advancements in COVID-19 Vaccines

Shao-Cheng Wang et al. Microorganisms. .

Abstract

Vaccination is the most effective method for the prevention of COVID-19 caused by SARS-CoV-2, which is still a global epidemic. However, the evolution of SARS-CoV-2 is so rapid that various variants, including the Alpha, Beta, Gamma, Delta, and Omicron variants, have emerged, lowering the protection rate of vaccines and even resulting in breakthrough infections. Additionally, some rare but severe adverse reactions induced by COVID-19 vaccines may raise safety concerns and hinder vaccine promotion; however, clinical studies have shown that the benefits of vaccination outweigh the risks caused by adverse reactions. Current vaccines approved with emergency use authorization (EUA) were originally adaptive for adults only, and infants, children, and adolescents are not included. New-generation vaccines are needed to overcome the challenges of limited adaptive age population, breakthrough infection (mainly due to virus variant emergencies), and critical adverse reactions. Fortunately, some advances in COVID-19 vaccines have been obtained regarding enlarged adaptive populations for clinical applications, such as the Pfizer/BioNTech vaccine and the Moderna vaccine. In this article, we provide a review on the challenges and recent advancements in COVID-19 vaccines. The development of next-generation COVID-19 vaccines should lay emphasis on the expansion of adaptive age populations in all individuals, the induction of immune responses to viral variants, the avoidance or alleviation of rare but potentially critical adverse reactions, and the discovery of subunit vaccines with adjuvants encapsulated in nanoparticles.

Keywords: COVID-19 vaccine; EUA; SARS-CoV-2; adverse reaction; breakthrough infection; viral variant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Impact of COVID-19 vaccines and development of next-generation vaccines.
See this image and copyright information in PMC

References

    1. Boopathi S., Poma A.B., Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J. Biomol. Struct. Dyn. 2020;39:3409–3418. doi: 10.1080/07391102.2020.1758788. - DOI - PMC - PubMed
    1. Mohamadian M., Chiti H., Shoghli A., Biglari S., Parsamanesh N., Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J. Gene Med. 2021;23:e3303. doi: 10.1002/jgm.3303. - DOI - PMC - PubMed
    1. Stout A.E., Millet J.K., Stanhope M.J., Whittaker G.R. Furin cleavage sites in the spike proteins of bat and rodent coronaviruses: Implications for virus evolution and zoonotic transfer from rodent species. One Health. 2021;13:100282. doi: 10.1016/j.onehlt.2021.100282. - DOI - PMC - PubMed
    1. Malik Y.A. Properties of Coronavirus and SARS-CoV-2. Malays. J. Pathol. 2020;42:3–11. - PubMed
    1. Kirtipal N., Bharadwaj S., Kang S.G. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect. Genet. Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502. - DOI - PMC - PubMed

LinkOut - more resources